Charles River to acquire Frontage's bioanalysis and DMPK operations for ~$470M

Charles River Laboratories announced a definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Pennsylvania for ~$470M in cash plus additional payments of up to $75M, expanding its capabilities in these research areas.

Detected & updated continuously · Source: Nebula